Neoplastic Syndromes, Hereditary

These syndromes are caused by inherited cancer predisposition, typically transmitted as an autosomal dominant trait with about 60% penetrance. The supplied grounding specifically links hereditary cancer risk to germline inactivation of mismatch repair genes in Lynch syndrome, which predisposes to mismatch repair-deficient cancers. The grounding also notes that NCCN guidance addresses high-penetrance genes associated with breast, ovarian, and pancreatic cancer, but does not provide a broader causal list.

The biological basis is inherited susceptibility to malignant transformation, with some hereditary cancers arising from defects in DNA mismatch repair. Loss of mismatch repair leads to microsatellite instability, insertion/deletion errors, and genomic instability, which can generate neoantigens and an inflamed tumor microenvironment. This mechanism is described in the context of mismatch repair-deficient tumors and their response to anti-PD-1 therapy.

A family history consistent with an autosomal dominant cancer predisposition is the defining risk factor. In the supplied grounding, inherited inactive mismatch repair alleles in Lynch syndrome confer a high risk of mismatch repair-deficient cancers. The NCCN abstract also highlights Ashkenazi Jewish ancestry as a context for genetic testing considerations in hereditary breast, ovarian, and pancreatic cancer risk assessment.

Management is described at the level of genetic testing and counseling for hereditary cancer syndromes, along with risk-management recommendations for people with syndromes associated with increased cancer risk. For mismatch repair-deficient tumors, immunotherapy with anti-PD-1 therapy is supported by the grounding, and the literature also notes that systemic therapy decisions may be informed by genetic testing. The supplied abstracts also mention targeted therapies in colorectal cancer, including vascular endothelial growth factor and epidermal growth factor receptor inhibitors, but not specifically as standard treatment for hereditary neoplastic syndromes as a whole.